| 48100-2 |
Cortisol^15M pre 1 ug/kg CRH IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --15 minutes pre 1 ug/kg CRH IV |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
|
|
|
|
|
|
CHAL |
|
48100-2 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 15M pre 1 ug/kg CRH IV SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; Before; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; i; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 48101-0 |
Cortisol^15M pre 1 ug/kg CRH IV |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --15 minutes pre 1 ug/kg CRH IV |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
48101-0 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 15M pre 1 ug/kg CRH IV SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; Before; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; i; Level; mcg; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.21 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 48102-8 |
Cortisol^4 AM specimen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --4 AM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
|
|
|
|
|
|
CHAL |
|
48102-8 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 4 AM specimen SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; Level; Mass concentration; Morning; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 48103-6 |
Cortisol^4 AM specimen |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --4 AM specimen |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
48103-6 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 4 AM specimen SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; Level; Morning; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR; Substance concentration |
2.7 |
2.21 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 48104-4 |
Cortisol^8 AM specimen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --8 AM specimen |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHAL |
|
48104-4 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 8 AM SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; Level; Mass concentration; Morning; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 48105-1 |
Cortisol^8 PM specimen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --8 PM specimen |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHAL |
|
48105-1 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 8 PM SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Evening; F; hydrocortisone; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 48106-9 |
4,5-Dihydroxyhexanolactone/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
4,5-Dihydroxyhexanolactone/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48106-9 |
|
|
|
|
Both |
|
|
|
0 |
4,5-DiOH-hexanolactone/Creat Ur-sRto |
|
|
|
N |
|
4,5-DHL; 4,5-dihydroxy-hexanoic acid lactone; 4,5-DiOH-hexanolactone; Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48107-7 |
Erythritol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Erythritol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
48107-7 |
|
|
|
|
Both |
|
|
|
0 |
Erythritol/Creat Ur-sRto |
|
|
|
N |
|
CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48108-5 |
Follitropin^15M pre 100 ug luteinizing releasing hormone IV |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --15 minutes pre 100 ug luteinizing releasing hormone IV |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
48108-5 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 15M pre 100 ug LRH IV SerPl-aCnc |
|
|
|
N |
|
15M pre 100 ug LRH IV; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; Horm; mcg; Pl; Plasma; Plsm; Point in time; pre 100 ug LRH IV; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
Release 2.69: COMPONENT: Corrected "lutenizing" to "luteinizing"; |
0 |
| 48109-3 |
Glucose^15M pre dose glucose |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose glucose |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHAL |
|
48109-3 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 15M pre glc SerPl-sCnc |
|
|
|
N |
|
15M pre glc; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Pl; Plasma; Plsm; Point in time; pre Glc; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.21 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 4811-6 |
HLA-B15 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B15 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4811-6 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B15 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48110-1 |
Glutathione.oxidized/glutathione.reduced |
SRto |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Glutathione.oxidized/Glutathione.reduced [Molar ratio] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
48110-1 |
|
|
|
|
Observation |
|
|
|
0 |
GSS/GSH RBC-sRto |
|
|
|
N |
|
Chemistry; Erythrocytes; GSH; GSS; GSSG; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Scrto; Substance concentration ratio; Substance ratio |
2.42 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 48111-9 |
Glutathione.reduced |
SCnt |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Glutathione.reduced [Moles/mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
umol/g Hb |
|
|
|
|
|
|
CHEM |
|
48111-9 |
|
|
|
|
Both |
|
|
|
0 |
GSH RBC-sCnt |
|
|
|
N |
|
Chemistry; Erythrocytes; GSH; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Substance content |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/g{Hb} |
|
|
|
0 |
| 48112-7 |
Glutathione.reduced |
ACnt |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Glutathione.reduced [Units/mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
U/g Hb |
|
|
|
|
|
|
CHEM |
|
48112-7 |
|
|
|
|
Both |
|
|
|
0 |
GSH RBC-aCnt |
|
|
|
N |
|
Arbitrary content; Chemistry; Erythrocytes; GSH; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles |
2.7 |
2.21 |
|
|
|
|
|
|
|
U/g{Hb} |
|
|
|
0 |
| 48113-5 |
Heptadecenoate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Heptadecenoate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48113-5 |
|
|
|
|
Both |
|
|
|
0 |
Heptadecenoate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Heptadecenoic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48114-3 |
Hexadecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Hexadecanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48114-3 |
|
|
|
|
Both |
|
|
|
0 |
Hexadecanedioate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Hexadecanedioic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48115-0 |
Homocysteine.free/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Homocysteine.free/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48115-0 |
|
|
|
|
Both |
|
|
|
0 |
Hcys.free/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; FR; HCY; Hcys; Hcys.free; Hcyst; Homocyst(e)ine; Non-protein bound; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48116-8 |
Insulin^10M pre dose glucose |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Units/volume] in Serum or Plasma --10 minutes pre dose glucose |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;uIU/mL |
|
|
|
|
|
|
CHAL |
|
48116-8 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 10M pre Glc SerPl-aCnc |
|
|
|
N |
|
10M pre Glc; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; NPH; Pl; Plasma; Plsm; Point in time; pre Glc; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.7 |
2.21 |
|
|
|
|
|
|
|
u[IU]/mL |
|
|
|
0 |
| 48117-6 |
Isovalerylglycine/Urea |
SRto |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Isovalerylglycine/Urea [Molar ratio] in Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/mmol |
|
|
|
|
|
|
CHEM |
|
48117-6 |
|
|
|
|
Observation |
|
|
|
0 |
Isovalerylgly/Urea Plas-sRto |
|
|
|
N |
|
Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio |
2.7 |
2.21 |
|
|
|
|
|
|
|
mmol/mmol |
|
|
|
0 |
| 48118-4 |
Lutropin^15M pre 100 ug luteinizing releasing hormone IV |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lutropin [Units/volume] in Serum or Plasma --15 minutes pre 100 ug luteinizing releasing hormone IV |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;IU/L |
|
|
|
|
|
|
CHAL |
|
48118-4 |
|
|
|
|
Observation |
|
|
|
0 |
LH 15M pre 100 ug LRH IV SerPl-aCnc |
|
|
|
N |
|
15M pre 100 ug LRH IV; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Horm; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; Leutinizing hormone; LH; Luteinizing hormone; Lutenin; Lutenizing hormone; mcg; Ovulation test; Pl; Plasma; Plsm; Point in time; pre 100 ug LRH IV; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
Release 2.69: COMPONENT: Corrected "lutenizing" to "luteinizing"; |
0 |
| 48119-2 |
Pentadecanoate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Pentadecanoate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48119-2 |
|
|
|
|
Both |
|
|
|
0 |
Pentadecanoate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Pentadecanoic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 4812-4 |
HLA-B16 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B16 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4812-4 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B16 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48120-0 |
Prolactin^15M pre dose TRH IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Prolactin [Mass/volume] in Serum or Plasma --15 minutes pre dose TRH IV |
|
MIN |
DefinitionDescription |
|
|
ng/mL;ug/L |
|
|
|
|
|
|
CHAL |
|
48120-0 |
|
|
|
|
Observation |
|
|
|
0 |
Prolactin 15M pre TRH IV SerPl-mCnc |
|
|
|
N |
|
15M pre TRH; 15M pre TRH IV; Before; CHEMISTRY.CHALLENGE TESTING; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; Pl; Plasma; Plsm; Point in time; pre TRH; pre TRH IV; PRL; Prol; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 48121-8 |
Quinolinate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Quinolinate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48121-8 |
|
|
|
|
Both |
|
|
|
0 |
Quinolinate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; Tryptophan metabolite; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48122-6 |
Somatotropin^15M post dose TRH |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose TRH |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48122-6 |
|
|
|
|
Both |
|
|
|
0 |
GH 15m p TRH SerPl-aCnc |
|
|
|
N |
|
15m p TRH; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; p dose; p TRH; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
